Company Focus
CSL Limited.
Latest CSL Limited. News
Biotechnology
Global biotechnology firm CSL Behring has announced that two patients with hemophilia B have been treated with the gene therapy Hemgenix (etranacogene dezaparvovec). 5 July 2024
Related News
Insights
Company Spotlight
A clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies for the treatment of cancer and infectious
diseases
Latest News & Features of interest to CSL Limited.
Biotechnology
American biotech Shattuck Labs has announced plans to reduce its workforce by approximately 40%, bringing its employee count below 50. 2 October 2024
Biotechnology
US vaccine company Gritstone bio closed 62% lower after Tuesday’s trading. 2 October 2024
Biotechnology
CSL Behring has been granted a positive recommendation by the Spanish Interministerial Commission on the Pricing of Medicines (CIPM), resulting in national reimbursement for Hemgenix (etranacogene dezaparvovec) for eligible haemophilia B patients in Spain. 1 October 2024
Pharmaceutical
Swiss pharma giant Roche sees itself as well-positioned to attack the lucrative obesity market. 1 October 2024
Pharmaceutical
Following a positive a positive European Medicines Agency recommendation in July, the European Commission (EC) has now approved Yuvanci (macitentan 10mg and tadalafil 40mg single tablet combination therapy [M/T STCT]). 1 October 2024
Pharmaceutical
ARS Pharmaceuticals' Neffy, the first needle-free epinephrine nasal spray, is poised to significantly impact the treatment of life-threatening allergic reactions like anaphylaxis. 1 October 2024
Pharmaceutical
Privately-held metabolic health specialist Rivus Pharmaceuticals has announced new clinical data from the Phase IIa HuMAIN study of HU6 in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) 1 October 2024
Biotechnology
Kezar Life Sciences saw its share tumble more than 42% to 40.77 yesterday, after it revealed it was voluntarily pausing enrollment of new patients and dosing of ongoing patients in the Phase IIb PALIZADE clinical trial, pending further evaluation. 1 October 2024
Biotechnology
Cambridge, USA-based Prime Medicine saw its shares rocket more than 38% to $4.78 today, as it revealed a strategic research collaboration and license agreement with Bristol Myers Squibb. 30 September 2024
Biotechnology
US RNAi therapeutics company Alnylam Pharmaceuticals has released two new data sets from the HELIOS-B Phase III study of Amvuttra (vutrisiran), an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). 30 September 2024
Latest In Brief for CSL Limited.
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Latest Relevant Ones To Watch News
California, USA-based biotech Nektar Therapeutics’ shares closed up more than 8% at $1.33 yesterday after it announced the sale of its only manufacturing facility. 5 November 2024
30 October 2024
26 October 2024
24 September 2024
19 September 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze